New updates have been reported about C Ray Therapeutics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
C-Ray Therapeutics has signed a Master Radioisotope Supply Agreement with SHINE Technologies that secures a long-term, GMP-grade supply of no-carrier-added lutetium-177 and grants C-Ray exclusive distribution rights for this key therapeutic isotope across mainland China, subject to certain existing SHINE partnerships. Under the deal, SHINE’s large-scale Cassiopeia facility in the U.S. will provide n.c.a. Lu-177 meeting both Chinese and U.S. regulatory standards, while C-Ray will handle distribution and downstream services through its 28,000-square-meter Chengdu site.
By combining exclusive Lu-177 access with its existing strength in actinium-225, C-Ray is positioning itself as a central infrastructure player for China’s targeted radiopharmaceutical therapy market, supporting domestic biotech developers, radiopharmaceutical firms, and hospitals with conjugation, fill-finish, and quality control capabilities. Management frames the agreement as a strategic supply diversification move that reduces historical isotope bottlenecks in China, enhances pipeline continuity for clients across oncology indications such as prostate cancer and neuroendocrine tumors, and is expected to accelerate clinical translation of radioligand therapies, with C-Ray’s CRDMO platform currently backing dozens of radioisotope programs spanning preclinical to Phase III stages.